Pfizer plans to farm out manufacturing for some of its drugs to make way for COVID-19 vaccine

Pfizer sign
Pfizer is in the early stages of human testing for its potential COVID-19 mRNA vaccine. (Pfizer)

Pfizer has dedicated enormous resources to churning out hundreds of millions of doses of a possible COVID-19 vaccine. But that massive effort requires a trade-off: Pfizer will have a hard time meeting production goals for its existing meds and will look to its contractor network to help keep up. 

Pfizer plans to outsource production of some of its drug portfolio to make way for a rapidly growing vaccine manufacturing effort, the company said Monday.

The drugmaker will lean on its 200-strong network of contractors as part of a plan to "build a robust U.S.-based supply chain as well as one based in Europe," a Pfizer spokesperson said.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Pfizer said it came to the outsourcing decision after determining that its COVID-19 shot rollout would heavily tax its ability to meet production goals, including its current 1.5 billion doses of sterile meds each year. 

"We determined that producing the volume of doses that we have committed to, in addition to our existing medicines and vaccines, will make significant demands on our network," the spokesperson said.

Pfizer's contracting network includes major players Lonza, Catalent and Thermo Fisher Scientific, among others, Pfizer's head of global supply Mike McDermott told Reuters last week. The drugmaker didn't specify which of its contractors would be tapped in the effort, Reuters said. 

The outlet said the outsourcing push would primarily target Pfizer's sterile drugs and vaccine portfolios. 

In parallel with its outsourcing push, Pfizer is also working to build up inventory for its drugs before manufacturing of the potential vaccine launches at scale. 

RELATED: Pfizer tags 3 U.S. manufacturing sites for possible COVID-19 vaccine launch

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.